The short answer
Cannabis products that cause drowsiness may add to impairment from azelastine nasal spray. Eye drops have much lower measured systemic exposure, so the nasal warning should not automatically be applied to ophthalmic use.
What this answer covers
Cannabis sativa oral preparations with potentially impairing cannabinoid content; not a blanket claim for hemp-seed food or every plant preparation. Nasal and ophthalmic medication routes adjudicated separately.
- Supplement or preparation
- Cannabis sativa
- Medication ingredient
- azelastine
Nasal spray carries an explicit warning
The inspected azelastine nasal-spray label reports somnolence and directs avoiding other CNS depressants because alertness can decrease further. This supports review of a sedating cannabinoid product before co-use.
Eye drops are a different exposure
The ophthalmic label reports generally very low plasma concentrations after repeated eye-drop use. It does not establish the same systemic sedative interaction as the nasal formulation. No exact cannabinoid-eye-drop trial was identified.
The cannabis ingredient matters
Prescription CBD can cause somnolence, while cannabis products vary substantially in THC, CBD and other ingredients. Plant identity alone does not establish a sedating dose. No measured azelastine-combination event rate or blood-level change was established.
Check the route before deciding
Tell the pharmacist whether you use nasal spray or eye drops and show the cannabinoid label. Follow the nasal product’s CNS-depressant advice where applicable; do not drive while impaired. No protective spacing interval was established.
Evidence and practical considerations
Side effects & toxicity
Conditional additive impairment for azelastine nasal spray with a sedating cannabinoid product. Not a universal claim for ophthalmic drops, hemp-seed food or every extract; no exact-pair incidence or PK finding.
- Exact scope
- Cannabis sativa oral preparations with potentially impairing cannabinoid content; not a blanket claim for hemp-seed food or every plant preparation. Nasal and ophthalmic medication routes adjudicated separately. with Azelastine hydrochloride nasal spray; ophthalmic drops considered separately.
- Medication form and route
- intranasal medication; ophthalmic medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed azelastine
Nasal spray may cause somnolence; avoid concurrent CNS depressants because alertness can decrease further.
How this applies: Exact azelastine RxCUI 18603 IN, with stated salt/formulation/route bridge.
No exact supplement-combination incidence or validated protective spacing; salt, route and release form limits apply.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed azelastine
Ophthalmic0.05% azelastine hydrochloride: measured plasma concentrations generally 0.02–0.25 ng/mL after 56 days of eye-drop treatment. Not the nasal CNS-depressant avoidance instruction.
How this applies: Exact azelastine RxCUI 18603 IN, with stated salt/formulation/route bridge.
Same active ingredient, different formulation or combination. Product-specific results cannot be transferred as identical exposure.
Source 3: Federal supplement guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: People considering the named botanical or supplement.
THC affects mental state; products containing THC, CBD and other plant materials differ substantially. Dizziness and impairment are reported for some cannabinoid preparations.
How this applies: Interpreted for azelastine only within the stated exact preparation and endpoint limits.
Oral cannabinoid preparations vary; hemp-seed foods and nonintoxicating plant materials are not equivalent to THC-containing products. No exact nasal or ocular azelastine risk estimate.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Prepared exact azelastine article with formulation-specific evidence and uncertainty. |
Article revision: 9c145e4af4a17c6d
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.